Blake Aftab - Oct 12, 2022 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Role
Chief Scientific Officer
Signature
/s/ Nick Harvey, Attorney-in-Fact
Stock symbol
ACET
Transactions as of
Oct 12, 2022
Transactions value $
-$126,638
Form type
4
Date filed
10/14/2022, 04:08 PM
Previous filing
Aug 8, 2022
Next filing
Oct 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACET Common Stock Options Exercise $25K +3.39K +6.85% $7.38 52.8K Oct 12, 2022 Direct F1
transaction ACET Common Stock Sale -$25.3K -1.65K -3.12% $15.40* 51.2K Oct 12, 2022 Direct F1
transaction ACET Common Stock Tax liability -$126K -7.93K -15.5% $15.92* 43.2K Oct 13, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACET Stock Option (Right to Buy) Options Exercise $0 -3.39K -5.65% $0.00 56.6K Oct 12, 2022 Common Stock 3.39K $7.38 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
F3 A total of 60,000 shares subject to an employee stock option were granted to the Reporting Person on October 12, 2021. 25% of the shares subject to the stock option vested and became exercisable on October 12, 2022, with the remainder vesting in equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continued service with the Issuer.